Legal status in the United States
Is MK-677 legal?
Read at FDA, DEA and WADAPublished by PepVault
MK-677 (ibutamoren) has no FDA-approved product (it is in a phase 3 trial), is not a federally controlled substance, and is banned in sport (WADA names it under S2.2.4), as of November 18, 2026.
MK-677 at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Not approved; in a phase 3 trial |
| Compounding | On FDA’s safety-risk list (category 2) |
| DEA schedule | Not controlled |
| Sport (WADA) | Banned, named (S2.2.4) |
FDA approval
MK-677 (ibutamoren) has no FDA-approved product: Drugs@FDA lists no application for it.
- Drugs@FDA data (openFDA): applications listing “IBUTAMOREN” as an active ingredient, U.S. Food and Drug Administration. Read .
In clinical trials
Lumos Pharma is testing it as LUM-201, by mouth, in a phase 3 trial in children with growth hormone deficiency (the record lists “ibutamoren mesylate”).
- ClinicalTrials.gov record NCT06948214: Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency, ClinicalTrials.gov (National Library of Medicine). Read .

Compounding
FDA keeps ibutamoren mesylate in category 2 for both pharmacies (503A, since September 29, 2023) and outsourcing facilities (503B, since December 29, 2022): bulk substances that may raise significant safety risks. FDA’s reason: a trial in people recovering from hip fracture was stopped early over a possible heart-failure signal.
The source: “Ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients.”
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA bans MK-677 at all times, in and out of competition: the 2026 list names ibutamoren (MK-677) among the growth hormone secretagogues under S2.2.4.
The source: “ibutamoren (MK-677), ipamorelin”
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
How it is sold when it isn’t approved
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.
The source: falsely labeled “for research purposes” or “not for human consumption.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about MK-677 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is MK-677 FDA approved?
MK-677 (ibutamoren) has no FDA-approved product: Drugs@FDA lists no application for it. Lumos Pharma is testing it as LUM-201, by mouth, in a phase 3 trial in children with growth hormone deficiency (the record lists “ibutamoren mesylate”).
Is MK-677 a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is MK-677 banned in sport?
WADA bans MK-677 at all times, in and out of competition: the 2026 list names ibutamoren (MK-677) among the growth hormone secretagogues under S2.2.4.
What does FDA say about compounding MK-677?
FDA keeps ibutamoren mesylate in category 2 for both pharmacies (503A, since September 29, 2023) and outsourcing facilities (503B, since December 29, 2022): bulk substances that may raise significant safety risks. FDA’s reason: a trial in people recovering from hip fracture was stopped early over a possible heart-failure signal.
What does FDA say about the “research use only” label?
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.